Trametes versicolor mushroom immune therapy in breast cancer

Journal of the Society for Integrative Oncology

Volumn 6, Issue 3, 2008, Pages 122-128

  Standish, Leanna J ^a   Wenner, Cynthia A ^a   Sweet, Erin S ^a   Bridge, Carly ^a   Nelson, Ana ^a   Martzen, Mark ^a   Novack, Jeffrey ^a   Torkelson, Carolyn ^b  

^a BASTYR UNIVERSITY   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Botanical medicine; Breast cancer; Immune therapy; Medicinal mushroom; Trametes versicolor

Indexed keywords

ANTINEOPLASTIC AGENT; BETA GLUCAN; CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 8; KRESTIN; LEVAMISOLE; MITOMYCIN C; MONOCLONAL ANTIBODY; NATURAL PRODUCT; PEPTIDOGLYCAN POLYSACCHARIDE; PREDNISOLONE; TAMOXIFEN; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ACUTE TOXICITY; ADD ON THERAPY; ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CHRONIC TOXICITY; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE FREE SURVIVAL; DRUG TARGETING; ESOPHAGUS CANCER; HUMAN; IMMUNOMODULATION; MONOTHERAPY; MUSHROOM; NONHUMAN; PROTEIN TARGETING; REVIEW; SECONDARY PREVENTION; STOMACH CANCER; T LYMPHOCYTE; TRAMETES VERSICOLOR;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY; PHYTOTHERAPY; PLANT EXTRACTS; TRAMETES;

EID: 51549120345     PISSN: 1715894X     EISSN: None     Source Type: Journal    
DOI: 10.2310/7200.2008.0016     Document Type: Review

References (78)

1. Ooi VE, Liu F. Immunomodulation and anti-cancer activity of polysaccharide-protein complexes. Curr Med Chem 2000;7:715-29.
2. Kidd PM. The use of mushroom glucans and proteoglycans in cancer treatment. Altern Med Rev 2000;5:4-27.
3. Sakamoto J, Koike A, Saji S, et al. Preoperative serum immunosuppressive acidic protein (IAP) test for the prognosis of gastric cancer: a statistical study of the threshold level and evaluation of the effect of the biological response modifier PSK. Surg Today 1992;22:530-6.
4. Maehara Y, Sugimachi K, Akagi M, et al. Early postoperative chemotherapy following noncurative resection for patients with advanced gastric cancer. Br J Cancer 1992;65:413-6.
5. Nio Y, Tsubono M, Tseng CC, et al. Immunomodulation by orally administered protein-bound polysaccharide Krestin (PSK)™ in patients with gastrointestinal cancer. Biotherapy 1992;4:117-28.
6. Kondo T, Sakamoto J, Nakazato H. Alternating immunochemotherapy of advanced gastric carcinoma: a randomized comparison of carbazilquinone and Krestin (PSK)™ to carbazilquinone in patients with curative gastric resection. Biotherapy 1991;3:287-95.
7. Maehara Y, Moriguchi S, Sakaguchi Y, et al. Adjuvant chemotherapy enhances long-term survival of patients with advanced gastric cancer following curative resection. J Surg Oncol 1990;45:169-72.
8. Imaizumi M, Kondo T, Kamei H, Ichihashi H. [Cooperative study on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer (II). Cooperative study group on surgical adjuvant immunochemotherapy for prevention of postoperative recurrence of gastric cancer supported by the Ministry of Health and Welfare (Kondo's group)]. Gan To Kagaku Ryoho 1990;17:2397-403.
9. Nakajima T, Inokuchi K, Hattori T, et al. [Multi-institutional cooperative study of adjuvant immunochemotherapy in gastric cancer - five-year survival rate]. Gan To Kagaku Ryoho 1989;16: 799-806.
10. Nakazato H, Koike A, Ichihashi H, et al. [An effect of adjuvant immunochemotherapy using Krestin and 5-FU on gastric cancer patients with radical surgery (first report) - a randomized controlled trial by the cooperative study group. Study Group of Immuno-chemotherapy with Krestin (PSK)™ for Gastric Cancer]. Gan To Kagaku Ryoho 1989;16:2563-76.
11. Tamada R, Inokuchi K, Hattori T, et al. [A multi-institutional study on postoperative adjuvant immunochemotherapy of gastric cancer (II)]. Gan To Kagaku Ryoho 1987;14:716-22.
12. Niimoto M, Hattori T, Tamada R, et al. Postoperative adjuvant immunochemotherapy with mitomycin C, futraful and Krestin (PSK)™ for gastric cancer. An analysis of data on 579 patients followed for five years. Jpn J Surg 1988;18:681-6.
13. Kanabe S, Tamakuma S, Mimura K, et al. [Comparison of immunochemotherapy and chemotherapy of stage IV gastric carcinoma]. Gan No Rinsho 1985;31:1805-9.
14. Nakazato H, Ichihashi H, Kondo T. [Clinical results of a randomized controlled trial on the effect of adjuvant immunochemotherapy using Esquinon and Krestin in patients with curatively resected gastric cancer. Cooperative Study Group of Cancer Immunochemotherapy, Tokai Gastrointestinal Oncology Group]. Gan To Kagaku Ryoho 1986;13:308-18.
15. Hirono M, Yoshinaka K, Matsuki K, et al. [Surgical treatment of Borrmann type 4 (diffuse) gastric cancer]. Gan No Rinsho 1984;30: 717-23.
16. Nakazato H, Koike A, Saji S, et al. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with Krestin (PSK)™ for Gastric Cancer. Lancet 1994;343:1122-6.
17. Osawa S, Shiroto H, Kondo Y, et al. [Randomized controlled study on adjuvant immunochemotherapy with carmofur (HCFU) for noncuratively resected and unresected gastric cancer]. Gan To Kagaku Ryoho 1996;23:327-31.
18. Sugimachi K, Maehara Y, Ogawa M, et al. Dose intensity of uracil and tegafur in postoperative chemotherapy for patients with poorly differentiated gastric cancer. Cancer Chemother Pharmacol 1997;40:233-8.
19. Ogoshi K, Tajima T, Mitomi T, et al. HLA-A2 antigen status predicts metastasis and response to immunotherapy in gastric cancer. Cancer Immunol Immunother 1997;45:53-9.
20. Saji S, Sakamoto J, Teramukai S, et al. Impact of splenectomy and immunochemotherapy on survival following gastrectomy for carcinoma: covariate interaction with immunosuppressive acidic protein, a serum marker for the host immune system. Tumor Marker Committee for the Study Group of Immunochemotherapy with Krestin (PSK)™ for Gastric Cancer. Surg Today 1999;29:504-10.
21. Toge T, Yamaguchi Y. Protein-bound polysaccharide increases survival in resected gastric cancer cases stratified with a preoperative granulocyte and lymphocyte count. Oncol Rep 2000;7:1157-61.
22. Ito K, Nakazato H, Koike A, et al. Long-term effect of 5-fluorouracil enhanced by intermittent administration of polysaccharide K after curative resection of colon cancer. A randomized controlled trial for 7-year follow-up. Int J Colorectal Dis 2004;19: 157-64.
23. Ueda Y, Fujimura T, Kinami S, et al. A randomized phase III trial of postoperative adjuvant therapy with S-1 alone versus S-1 plus Krestin (PSK)™ for stage II/IIIA gastric cancer: Hokuriku-Kinki Immunochemo-Therapy Study Group-Gastric Cancer (HKIT-GC). Jpn J Clin Oncol 2006;36:519-22.
24. Mitomi T, Tsuchiya S, Iijima N, et al. Randomized, controlled study on adjuvant immunochemotherapy with Krestin (PSK)™ in curatively resected. colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum (Kanagawa). Dis Colon Rectum 1992;35:123-30.
25. Torisu M, Hayashi Y, Ishimitsu T, et al. Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer. Cancer Immunol Immunother 1990;31:261-8.
26. Mitomi T, Tsuchiya S, Iijima N, et al. [Randomized controlled study on adjuvant immunochemotherapy with Krestin (PSK)™ in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum]. Gan To Kagaku Ryoho 1989;16:2241-9.
27. Takashima S, Kinami Y, Miyazaki I. (Clinical effect of postoperative adjuvant immunochemotherapy with the FT-207 suppository and Krestin (PSK)™ in colorectal cancer patients. Colorectal Cancer Chemotherapy Group in Hokuriku]. Gan To Kagaku Ryoho 1988;15:2229-36.
28. Ogoshi K, Satou H, Isono K, et al. Possible predictive markers of immunotherapy in esophageal cancer: retrospective analysis of a randomized study. The Cooperative Study Group for Esophageal Cancer in Japan. Cancer Invest 1995;13:363-9.
29. Ogoshi K, Satou H, Isono K, et al. Immunotherapy for esophageal cancer. A randomized trial in combination with radiotherapy and radiochemotherapy. Cooperative Study Group for Esophageal Cancer in Japan. Am J Clin Oncol 1995;18:216-22.
30. Munemoto Y, Iida Y, Abe J, et al. Significance of postoperative adjuvant immunochemotherapy after curative resection of colorectal cancers: association between host or tumor factors and survival. Int J Oncol 2002;20:403-11.
31. Shibata M, Nezu T, Kanou H, et al. Immunomodulatory effects of low dose cis-diaminedichloroplatinum (cisplatin) combined with UFT and Krestin (PSK)™ in patients with advanced colorectal cancer. Cancer Invest 2002;20:166-73.
32. Koda K, Miyazaki M, Sarashina H, et al. A randomized controlled trial of postoperative adjuvant immunochemotherapy for colorectal cancer with oral medicines. Int J Oncol 2003;23:165-72.
33. Ohwada S, Kawate S, Ikeya T, et al. Adjuvant therapy with protein-bound polysaccharide K and tegafur uracil in patients with stage II or III colorectal cancer: randomized, controlled trial. Dis Colon Rectum 2003;46:1060-8.
34. Ohwada S, Ikeya T, Yokomori T, et al. Adjuvant immunochemotherapy with oral tegafur/uracil plus Krestin (PSK)™ in patients with stage II or III colorectal cancer: a randomised controlled study. Br J Cancer 2004;90:1003-10.
35. Takahashi Y, Mai M, Nakazato H. Preoperative CEA and PPD values as prognostic factors for immunochemotherapy using Krestin (PSK)™ and 5-FU. Anticancer Res 2005;25:1377-84.
36. Ohwada S, Ogawa T, Makita F, et al. Beneficial effects of protein-bound polysaccharide K plus tegafur/uracil in patients with stage II or III colorectal cancer. analysis of immunological parameters. Oncol Rep 2006;15:861-8.
37. Matsui T, Omura K, Kawakami K, et al. Genotype of thymidylate synthase likely to affect efficacy of adjuvant 5-FU based chemotherapy in colon cancer. Oncol Rep 2006;16:1111-5.
38. Yamashita K, Ougolkov AV, Nakazato H, et al. Adjuvant immunochemotherapy with protein-bound polysaccharide K for colon cancer in relation to oncogenic beta-catenin activation. Dis Colon Rectum 2007;50:1169-81.
39. Ogoshi K. [Evaluation of immunotherapy with Krestin (PSK)™ in esophageal cancer]. Gan To Kagaku Ryoho 1988;15:3143-51.
40. Toi M, Hattori T, Akagi M, et al. Randomized adjuvant trial to evaluate the addition of tamoxifen and Krestin (PSK)™ to chemotherapy in patients with primary breast cancer. 5-Year results from the Nishi-Nippon Group of the Adjuvant Chemoendocrine Therapy for Breast Cancer Organization. Cancer 1992;70:2475-83.
41. Morimoto T, Ogawa M, Orita K, et al. Postoperative adjuvant randomised trial comparing chemoendocrine therapy, chemotherapy and immunotherapy for patients with stage II breast cancer: 5-year results from the Nishinihon Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer (ACETBC) of Japan. Eur J Cancer 1996;32A:235-42.
42. Iino Y, Yokoe T, Maemura M, et al. Immunochemotherapies versus chemotherapy as adjuvant treatment after curative resection of operable breast cancer. Anticancer Res 1995;15:2907-11.
43. Yokoe T, Iino Y, Takei H, et al. HLA antigen as predictive index for the outcome of breast cancer patients with adjuvant immunochemotherapy with PSK. Anticancer Res 1997;17:2815-8.
44. Fisher M, Yang LX. Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy. Anticancer Res 2002;22:1737-54.
45. Yang QY. Yuri Zhi polysaccharopeptide (PSP) and the general aspects of its research. Fung Sci 1997;12:1-8.
46. Tsang KW, Lam CL, Yan C, et al. Coriolus versicolor polysaccharide peptide slows progression of advanced non-small cell lung cancer. Respir Med 2003;97:618-24.
47. Hayakawa K, Mitsuhashi N, Saito Y, et al. Effect of Krestin (PSK) as adjuvant treatment on the prognosis after radical radiotherapy in patients with non-small cell lung cancer. Anticancer Res 1993; 13:1815-20.
48. Yoshino S, Oka M, Hazama S, Suzuki T. [Effect of intrapleural and/or intraperitoneal lentinan therapy in carcinomatous pleuritis and peritonitis]. Gan To Kagaku Ryoho 1990;17:1588-91.
49. Kanazawa M, Yoshihara K, Abe H, et al. Effects of Krestin (PSK)™ on T and dendritic cells differentiation in gastric or colorectal cancer patients. Anticancer Res 2005;25:443-9.
50. Sakamoto J, Morita S, Oba K, et al. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials. Cancer Immunol Immunother 2006;55:404-11.
51. Lindequist U, Niedermeyer TH, Julich WD. The pharmacological potential of mushrooms. Evid Based Complement Alternat Med 2005;2:285-99.
52. Hobbs C. Medicinal value of turkey tail fungus Trametes versicolor (L.:Fr.) Pilat (aphyllophoromycetideae). Int J Med Mushrooms 2004;6:195-218.
53. Kobayashi H, Matsunaga K, Oguchi Y. Antimetastatic effects of Krestin (PSK)™ (Krestin), a protein-bound polysaccharide obtained from basidiomycetes: an overview. Cancer Epidemiol Biomarkers Prev 1995;4:275-81.
54. Go P, Chung CH. Adjuvant Krestin (PSK)™ immunotherapy in patients with carcinoma of the nasopharynx. J Int Med Res 1989; 17:141-9.
55. Sugimachi K, Inokuchi K, Matsuura H, et al. Hormone conditioned cancer chemotherapy for recurrent breast cancer prolongs survival. Jpn J Surg 1984;14:217-21.
56. Ikuzawa M, Matsunaga K, Nishiyama S, et al. Fate and distribution of an antitumor protein-bound polysaccharide Krestin (PSK)™. Int J Immunopharmacol 1988;10:415-23.
57. Hayashida Y, Kurimoto S, Yamamoto N. Effect of lymphokine-activated killer cells on human retinoblastoma cells (Y-79) in vitro: enhancement of the activity by a polysaccharide preparation, Krestin. Biochem Biophys Res Commun 1991;174:107-14.
58. Hirose K, Zachariae CO, Oppenheim JJ, Matsushima K. Induction of gene expression and production of immunomodulating cytokines by Krestin (PSK)™ in human peripheral blood mononuclear cells. Lymphokine Res 1990;9:475-83.
59. Kato M, Hirose K, Hakozaki M, et al. Induction of gene expression for immunomodulating cytokines in peripheral blood mononuclear cells in response to orally administered PSK, an immunomodulating protein-bound polysaccharide. Cancer Immunol Immunother 1995;40:152-6.
60. Liu F, Fung MC, Ooi VE, Chang ST. Induction in the mouse of gene expression of immunomodulating cytokines by mushroom polysaccharide-protein complexes. Life Sci 1996;58:1795-803.
61. Ohmura Y, Matsunaga K, Motokawa I, et al. Protective effects of a protein-bound polysaccharide, PSK, on Candida albicans infection in mice via tumor necrosis factor-alpha induction. Int Immunopharmacol 2001;1:1797-811.
62. Mizutani Y, Yoshida O. Activation by the protein-bound polysaccharide Krestin (PSK)™ (Krestin) of cytotoxic lymphocytes that act on fresh autologous tumor cells and T24 human urinary bladder transitional carcinoma cell line in patients with urinary bladder cancer. J Urol 1991;145:1082-7.
63. Kariya Y, Inoue N, Kihara T, et al. Activation of human natural killer cells by the protein-bound polysaccharide Krestin (PSK)™ independently of interferon and interleukin 2. Immunol Lett 1992; 31:241-5.
64. Habelhah H, Okada F, Nakai K, et al. Polysaccharide K induces Mn superoxide dismutase (Mn-SOD) in tumor tissues and inhibits malignant progression of QR-32 tumor cells: possible roles of interferon alpha, tumor necrosis factor alpha and transforming growth factor beta in Mn-SOD induction by polysaccharide K. Cancer Immunol Immunother 1998;46:338-44.
65. Harada M, Matsunaga K, Oguchi Y, et al. Oral administration of Krestin (PSK)™ can improve the impaired anti-tumor CD4+ T-cell response in gut-associated lymphoid tissue (GALT) of specific-pathogen-free mice. Int J Cancer 1997;70:362-72.
66. Wada T, Iijima H, Sekine F, et al. [Effect of Krestin (PSK)™ on Th1/ Th2 balance in tumor-bearing mice]. Gan To Kagaku Ryoho 2003; 30:1798-801.
67. Okuzawa M, Shinohara H, Kobayashi T, et al. PSK, a protein-bound polysaccharide, overcomes defective maturation of dendritic cells exposed to tumor-derived factors in vitro. Int J Oncol 2002;20:1189-95.
68. Yagita A, Maruyama S, Wakasugi S, Sukegawa Y. H-2 haplotype-dependent serum IL-12 production in tumor-bearing mice treated with various mycelial extracts. In Vivo 2002;16:49-54.
69. Yefenof E, Gafanovitch I, Oron E, et al. Prophylactic intervention in radiation-leukemia-virus-induced murine lymphoma by the biological response modifier polysaccharide K. Cancer Immunol Immunother 1995;41:389-96.
70. Qian ZM, Xu MF, Tang PL. Polysaccharide peptide (PSP) restores immunosuppression induced by cyclophosphamide in rats. Am J Chin Med 1997;25:27-35.
71. Mizutani Y, Yoshida O. Activation by the protein-bound polysaccharide Krestin (PSK)™ (Krestin) of cytotoxic lymphocytes that act on fresh autologous tumor cells and T24 human urinary bladder transitional carcinoma cell line in patients with urinary bladder cancer. J Urol 1991;145:1082-7.
72. Nio Y, Shiraishi T, Tsubono M, et al. In vitro immunomodulating effect of protein-bound polysaccharide, Krestin (PSK)™ on peripheral blood, regional nodes, and spleen lymphocytes in patients with gastric cancer. Cancer Immunol Immunother 1991;32:335-41.
73. Garcia-Lora A, Martinez M, Pedrinaci S, Garrido F. Different regulation of PKC isoenzymes and MAPK by Krestin (PSK)™ and IL-2 in the proliferative and cytotoxic activities of the NKL human natural killer cell line. Cancer Immunol Immunother 2003;52:59-64.
74. Garcia-Lora A, Pedrinaci S, Garrido F. Protein-bound polysaccharide K and interleukin-2 regulate different nuclear transcription factors in the NKL human natural killer cell line. Cancer Immunol Immunother 2001;50:191-8.
75. Schmidt C. Immune system's Toll-like receptors have good opportunity for cancer treatment. J Natl Cancer Inst 2006;98:574-5.
76. Price LA. Medicinal mushroom-induced activation of macrophages and splenocytes is mediated by the toll 4 receptor. North American Conference on Complementary and Alternative Medicine. 2007.
77. Hong F, Hansen RD, Yan J, et al. Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. Cancer Res 2003;63:9023-31.
78. Modak S, Koehne G, Vickers A, et al. Rituximab therapy of lymphoma is enhanced by orally administered (1->3),(1->4)-D-beta-glucan. Leuk Res 2005;29:679-83.